Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
March 12, 2001
- Hokuriku: Hokunalin Tape, Ganaton Boost Sales, Operating Profits
March 12, 2001
- Taisho Signs Anti-Asthma Drug License Agreement with EpiGenesis
March 12, 2001
- JMARI to Conduct Survey to Propose New Medical Fee Payment Method
March 12, 2001
- Over 90% of Nursing Staff Have Committed or Nearly Committed Errors
March 12, 2001
- Japan Tobacco to Make Pharma Business Profitable in FY2005
March 12, 2001
- BUSINESS NEWS IN BRIEF -2-
March 12, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 12, 2001
- Dainippon to Report Record-high Sales, Profits Again: President Miyatake
March 12, 2001
- Strategic Value of Product Forecasting Is Critical: Dr Ramsey of Mattson Jack Group
March 12, 2001
- Chugai Forms Functional Genomics Alliance with Immusol
March 12, 2001
- Domestic Market for CRO Business Estimated to Be \150 Bil.: CMIC President
March 12, 2001
- Next-generation Vitamin D Expected to Be Effective for Colon Cancer: Chugai Seminar
March 12, 2001
- IFPMA Creates Task Force on Access to Anti-AIDS Drugs
March 12, 2001
- Actelion to Launch First Endothelin Receptor Antagonists: JPLA Meeting
March 12, 2001
- Mitsubishi Chemical, Fujitsu Tie Up for Bioinformatics
March 12, 2001
- MEDICAL DEVICE NEWS IN BRIEF
March 12, 2001
- Tanabe Licenses PDE5 Inhibitor to Vivus
March 12, 2001
- Panic Disorder Is Curable by Drug Therapy: GSK Seminar
March 12, 2001
- WORLD BUSINESS NEWS IN BRIEF
March 12, 2001
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…